Innovation
2 patent families — focus: Chemistry & metallurgy, Human necessities; filing pace steady. Cited 32 times.
| Year | Filings |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
Investor mix
1 investor on record.
| Investor type | Count | Share |
|---|---|---|
| Other / undisclosed | 1 | 100% |
Chimeric fibril-reactive monoclonal antibody (mAb) for the treatment of AL Amyloidosis
2 patent families — focus: Chemistry & metallurgy, Human necessities; filing pace steady. Cited 32 times.
| Year | Filings |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
1 investor on record.
| Investor type | Count | Share |
|---|---|---|
| Other / undisclosed | 1 | 100% |